An anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.
Xinhua Asia-Pacific news summary at 1600 GMT, May 8 centralasiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from centralasiatimes.com Daily Mail and Mail on Sunday newspapers.
'DRDO's anti-Covid 2-DG drug effective against different variants'
'DRDO's anti-Covid 2-DG drug effective against different variants'
Last Updated: Sun, May 9th, 2021, 03:25:51hrs
New Delhi: The Defence Research and Development Organisation (DRDO)'s new anti-COVID drug, just approved by the Drugs Controller General of India (DCGI) is effective against different variants of the coronavirus and helps in bringing patients out of oxygen support, said DRDO scientists.
Dr Anant Narayan Bhatt, a scientist at the DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS-DRDO) while speaking to ANI said, "In the Phase 3 trials for 2-deoxy-D-glucose (2-DG), a large number of patients were tested and it was found that many patients are coming out of oxygen (support)... The mechanism of action is very unique and as per the basics principles of this drug, it will be very effective on different variants of the SARS-CoV-2 virus."
Coronavirus live updates | Recovery rate plummets to 70% in Karnataka
Updated:
Updated:
May 09, 2021 09:29 IST
The DCGI granted permission for emergency use of an anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose, developed by INMAS, a lab of the DRDO, in collaboration with Dr. Reddy’s Laboratories.
Share Article
AAA
A view of 100-bed Covid isolation facility at Calvary Temple, in Hyderabad on Saturday, May 8, 2021.
| Photo Credit: RAMAKRISHNA G
The DCGI granted permission for emergency use of an anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose, developed by INMAS, a lab of the DRDO, in collaboration with Dr. Reddy’s Laboratories.
Requirement of a positive test for the COVID-19 virus is not mandatory for admission to a COVID-19 health facility and no patient will be refused services on any count, the Health Ministry said on Saturday, announcing the revised national policy for admission to various categories of COVID-19 facilities.
DRDO's anti-COVID drug is safe, will help patients recover faster: Dr Sudhir Chandna ANI | Updated: May 09, 2021 13:58 IST
New Delhi [India], May 9 (ANI): Dr Sudhir Chandna, Institute of Nuclear Medicine and Allied Sciences (INMAS) scientist, on Sunday said the recently approved anti-COVID drug 2-deoxy-D-glucose (2-DG) is completely safe and will help patients recover faster.
2-DG has been developed by INMAS, a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories (DRL), Hyderabad.
"During clinical trials, it has yielded an effective result in curing patients infected with COVID-19. The medicine has gone through clinical trials on around 110 patients in the second phase. In the third phase, it was tried on 220 patients. It has shown better efficacy in phase two itself as compared to the standard care," Dr Chandna said.
India records 4.3 lakh new COVID-19 cases, over 4000 deaths in last 24 hours On Friday, India had recorded 4,01,078 new cases of COVID-19 and 4,187 fatalities â the highest single-day spike in deaths.
Share
Updated: May 9, 2021, 01:44 PM IST
The second wave of Covid-19 continues to wreak havoc in India with the country reporting three to four lakh new cases every week. Restrictions like lockdown are implemented in almost all the states of the country to reduce Covid-19 cases, yet the cases are not decreasing. This is the fifth time in a week when India has crossed the 4 lakh mark of new cases in 24 hours. On Friday, India had recorded 4,01,078 infections and 4,187 fatalities – the highest single-day spike in deaths.
May 09, 2021, 12:49 IST
The therapeutic application of the 2-deoxy-D-glucose (2-DG) drug for the treatment of Covid patients was approved by the Drugs Controller General of India (DCGI). The anti- Covid drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.
Government officials said that the clinical trial results of this module have shown that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. "The drug will be of immense benefit to people suffering from Covid-19,” they added.
The Drugs Controller General of India (DGCI) has approved an anti-COVID drug developed by the Defence Research and Development Organisation (DRDO) for emergency use.
Uttarakhand: DRDO setting up COVID care hospitals in Haldwani, Rishikesh ANI | Updated: May 09, 2021 09:28 IST
Haldwani/Rishikesh (Uttrakhand) [India], May 9 (ANI): In view of rising cases of COVID-19, DRDO is building two COVID care hospitals in Haldwani and Rishikesh in Uttarakhand.
According to the DRDO officials, the hospital in Haldwani will have 500 beds, with 375 oxygen beds and 125 ventilator beds while the one in Rishikesh will have 400 oxygen beds and 100 ventilator beds.
Earlier, DRDO had set up a 750-bedded makeshift COVID hospital at Banaras Hindu University premises and has started construction of a 500-bed COVID-19 hospital in Budgam district to ramp up medical infrastructure.
6720
New Delhi, May 8
The Drugs Controller General of India (DCGI) has granted emergency use approval to DRDO-developed oral drug to treat Covid, the Ministry of Defence said today.
The drug, 2-deoxy-D-glucose (2-DG), has been cleared for adjunct therapy in moderate to severe patients. A generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.
How it works
It accumulates in virus-infected cells and prevents virus growth
It stops viral synthesis and energy production; ensures faster recovery
The drug has been developed by DRDO’s Institute of Nuclear Medicine and Allied Sciences in collaboration with Dr Reddy’s Laboratories, Hyderabad. It comes in powder form and is taken orally by dissolving it in water. The drug accumulates in virus-infected cells and prevents virus growth by stopping viral synthesis and energy production.